Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Sermorelin

GHRH (1-29), GRF 1-29 NH2, Sermorelin acetate

Quick Stats
Studies 223
Trials 41
Score 3
1996 pubmed

Characterization of the hypothalamo-pituitary-IGF-I axis in rats made obese by overfeeding.

Cattaneo. L L; De Gennaro Colonna. V V; Zoli. M M; Müller. E E; Cocchi. D D

Key Findings

  • Obese rats showed a significantly smaller GH spike after a supramaximal GHRH injection compared to lean controls
  • Pituitary GH content, GH gene expression, and free IGF‑I levels were unchanged across groups
  • Hypothalamic GHRH and somatostatin mRNA levels did not differ, indicating the impairment is peripheral rather than central

Practical Outcomes

  • If you’re using sermorelin (a GHRH analog) to boost GH, excess body fat may blunt its effectiveness. Losing weight could restore a normal GH response, making the peptide work better. Keep an eye on metabolic markers like glucose, insulin, and testosterone, as they also shift with obesity and can influence overall hormone balance.

Summary

In rats that became obese by eating a high‑calorie diet, their bodies released less growth hormone (GH) when given a burst of GHRH, even though the pituitary gland still had normal GH stores and IGF‑I levels were unchanged. This reduced GH response seems to come from factors outside the brain, not from a lack of GHRH signals, and it goes away when the animals lose weight.

Abstract

Obesity is coupled to several disturbances of the endocrine axes. It has previously been shown that genetically obese Zucker male rats have an impaired secretion of growth hormone (GH), probably originating from a primary reduction of hypothalamic GH-releasing hormone (GHRH) function and resulting in a decrease of GH gene expression and release. We sought to evaluate the somatotropic function in another model of experimental obesity. Normal male Sprague-Dawley rats were fed an energy-rich highly palatable diet for 7 months until they reached body weights overlapping those reported for obese Zucker rats. They were then evaluated for different indices of the hypothalamo-pituitary-somatomedin-C (IGF-I) axis. At the end of the overfeeding period, rats were divided into overtly obese (obese group) and overweight (overweight group) rats according to the degree of overweight and the Obesity Lee Index, while rats fed ad libitum with the standard pellet chow served as controls. Acute administration of a supramaximal dose of GHRH (2 micrograms/rat i.v.) elicited a significantly (at least P < 0.05) lower plasma GH rise in the overweight and obese groups compared with the controls although no difference was seen in the pituitary GH content and gene expression and plasma concentrations of free IGF-I in the two experimental groups vs the controls. In addition, evaluation of hypothalamic GHRH and somatostatin mRNAs (slot-blot hybridization) did not show any significant differences between the three groups. Of the different metabolic indices investigated, plasma glucose and insulin concentrations were significantly (P < 0.01) higher in the obese than in the overweight and control groups. A sharp decrease in plasma testosterone levels, together with a reduction in testis weight, was seen in both groups of rats fed the palatable diet compared with the controls. These findings underline the 'peripheral' feature of the hyposomatotropinism of rats chronically fed an energy-rich diet, and may account for the reversibility of the GH impairment in many obese subjects once a normal body weight has been restored. Moreover, the peripherally-driven hyposomatotropinism of these rats is in sharp contrast with the hypothalamic-driven GH secretory impairment of the obese Zucker rats.

Study Information

Provider

pubmed

Year

1996

DOI

10.1677/joe.0.1480347